MedTech Dive July 15, 2024
The heart valve specialist said Monday in a federal filing that it expects to pay $300 million in cash for Innovalve Bio Medical when the deal closes.
Dive Brief:
- Edwards Lifesciences said Monday it exercised an option to buy Innovalve Bio Medical, an Israel-based startup that is developing transcatheter mitral valve replacement technologies.
- Edwards expects to pay about $300 million in cash at the closing of the acquisition, which is forecasted for the end of 2024, according to a Monday Securities and Exchange Commission filing.
- In a separate deal announced Friday, Edwards agreed to pay 15 million euros (about $16.3 million) for a stake in France’s Affluent Medical and access to its technologies. The agreements include an exclusive...
Today's Sponsors
Today's Sponsor